AbCellera Biologics Inc. (FRA:8QQ)
Germany · Delayed Price · Currency is EUR 3.250
+0.144 (4.64%)
At close: Nov 28, 2025
AbCellera Biologics Company Description
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.
| Country | Canada |
| Founded | 2012 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 596 |
| CEO | Carl Hansen |
Contact Details
Address: 150 West 4th Ave Vancouver, British Columbia V5Y 1G6 Canada | |
| Phone | 604 559 9005 |
| Website | abcellera.com |
Stock Details
| Ticker Symbol | 8QQ |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Carl Hansen | Chief Executive Officer |
| Andrew Booth | Chief Financial Officer |
| Andrew Knowles | Chief Operating Officer |